title: Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients.
abstract: 72 consecutive patients with suspected parkinsonian syndromes (PS) were studied by dopamine transporter (DAT) and D2 receptor SPECT in order to evaluate the accuracy of combined SPECT imaging. In the follow-up, the patients were diagnosed as having Parkinson's disease (PD, n = 25), dementia with Lewy bodies (DLB, n = 6), multiple system atrophy (MSA, n = 13), progressive supranuclear palsy (PSP, n = 8), corticobasal degeneration (CBD, n = 9), and essential tremor (ET, n = 11). Using the iteratively estimated optimal cutoffs, DAT was reduced in 57/61 PS patients, whereas all ET patients were identified as "normal". Reduced D2 receptor binding had 7/13 patients with MSA, 6/8 patients with PSP, 2/9 patients with CBD and no ET, PD or DLB patients. FP-CIT SPECT allows an accurate detection of nigrostriatal affection in neurodegenerative PS. IBZM SPECT is useful to approve the diagnosis of PSP and MSA although a normal finding cannot exclude an atypical PS. IBZM SPECT seems to be of restricted value in CBD.
authors.affiliation: Klinik für Strahlenheilkunde, Campus Virchow-Klinikum, Charité Universitätsmedizin, Berlin, Germany. michail.plotkin@charite.de
authors.forename: M
authors.initials: M
authors.lastname: Plotkin
authors.forename: H
authors.initials: H
authors.lastname: Amthauer
authors.forename: S
authors.initials: S
authors.lastname: Klaffke
authors.forename: A
authors.initials: A
authors.lastname: Kühn
authors.forename: L
authors.initials: L
authors.lastname: Lüdemann
authors.forename: G
authors.initials: G
authors.lastname: Arnold
authors.forename: K-D
authors.initials: KD
authors.lastname: Wernecke
authors.forename: A
authors.initials: A
authors.lastname: Kupsch
authors.forename: R
authors.initials: R
authors.lastname: Felix
authors.forename: S
authors.initials: S
authors.lastname: Venz
mesh_terms: D000368:Aged; D001549:Benzamides; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020734:Parkinsonian Disorders / Q000175:diagnosis*; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon; D014326:Tropanes
chemical_list: D001549:Benzamides; D050483:Dopamine Plasma Membrane Transport Proteins; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D014326:Tropanes; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide